Loading...
•
Sep 30, 2020
Generation Bio Q3 2020 Earnings Report
Generation Bio's financial position was updated and key leadership team members were appointed.
Key Takeaways
Generation Bio reported a net loss of $20.8 million for the third quarter of 2020. The company's cash, cash equivalents, and marketable securities totaled $280.4 million as of September 30, 2020. Key leadership appointments were also announced to support preclinical development programs.
Cash, cash equivalents and marketable securities were $280.4 million as of September 30, 2020.
Research and development expenses were $15.3 million for the quarter ended September 30, 2020.
General and administrative expenses were $5.7 million for the quarter ended September 30, 2020.
Net loss was $20.8 million for the quarter ended September 30, 2020.
Generation Bio
Generation Bio
Forward Guidance
Generation Bio anticipates development candidate selection and initiation of IND-enabling studies for hemophilia A and PKU in 2021.
Positive Outlook
- Development candidate selection for hemophilia A in 2021
- Development candidate selection for PKU in 2021
- Initiation of IND-enabling studies for hemophilia A in 2021
- Initiation of IND-enabling studies for PKU in 2021